对Ocadusertib的早期开发,Ocadusertib是一种选择性受体相互作用的血清/氨酸-蛋白激酶1抑制剂
Simon J Shaw1, Vanessa C Taylor1, Jonathan T Sims2
1Rigel Pharmaceuticals, Inc., South San Francisco, California, USA.
Clinical and translational science
|March 6, 2026
概括
奥卡杜塞蒂布 (Ocadusertib) 是一种强大的与受体相互作用的氨酸/氨酸蛋白激酶1 (RIPK1) 抑制剂,在慢性炎症性疾病中表现有前途. 第1阶段试验显示了良好的耐受性,目标参与和在人类中有利的药理动力学.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 药物开发 药物开发
背景情况:
- 与受体相互作用的氨酸/氨酸蛋白激酶1 (RIPK1) 抑制剂正在研究慢性炎症状况,如类风湿性关节炎,炎症性肠病和牛皮.
- 奥卡杜塞尔蒂布是一种选择性,全性RIPK1抑制剂,目前正在临床试验中.
研究的目的:
- 提供关于ocadusertib发展的临床前和第一期临床数据.
- 评估其药理动力学,安全性和目标参与度.
主要方法:
- 临床前研究评估了ocadusertib在小鼠模型中的酶和细胞活性,选择性和体内疗效.
- 在健康参与者的第一阶段试验中,在单剂和多剂后评估了药理动力学,安全性,耐受性和RIPK1目标激活.
主要成果:
- 奥卡杜塞尔蒂布显示出强烈的RIPK1抑制 (IC50: 12-38 nM),并阻断了死细胞的反应.
- 它对RIPK1具有很高的选择性,并在小鼠模型中减少了疾病严重程度.
- 第1期试验显示了线性药理动力学,剂量相称的暴露和良好的耐受性,在第14天超过90%的RIPK1目标参与率.
结论:
- 奥卡杜塞尔蒂布表现出有利的临床前和早期临床特征.
- 这些发现支持进一步调查ocadusertib用于治疗慢性炎症疾病.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
7.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.9K
Receptor Tyrosine Kinases
20.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.2K
GPCR Desensitization
8.5K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.5K
Drug-Receptor Interaction: Antagonist
5.3K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.3K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
cAMP-dependent Protein Kinase Pathways
8.8K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.8K


